Bio

Dr. Wu is a board-certified cardiologist at Stanford Health Care. He is also a clinical assistant professor in the Division of Cardiovascular Medicine. His areas of clinical focus include general and preventive cardiology with a particular interest in cardiac imaging. Dr. Wu has board certification in echocardiography, cardiovascular CT, and cardiac nuclear imaging.

Dr. Wu speaks fluent Chinese and Spanish and embraces racial, ethnic, and socioeconomic diversity in his clinical care. He has international clinical/research experiences in Italy and Mexico, and truly enjoys meeting and working with people from distinctive backgrounds.

Dr. Wu is passionate about clinical research. He has pursued scholarly work on the utilization of therapeutic drug monitoring for antihypertensive therapy and statins to help patients from low socioeconomic backgrounds improve their medication adherence. He is also involved in research on advanced cardiac imaging and has actively investigated the applications of cardiac CT in electrophysiology interventions.

Dr. Wu’s research has been published in peer-reviewed journals such as the International Journal of Cardiology and Journal of Vascular Surgery. He has presented his work at regional and national meetings, including the American Heart Association’s annual Scientific Sessions.

Dr. Wu is a member of the American College of Physicians, American Heart Association, and American Medical Association.

Clinical Focus

  • Cardiovascular Disease

Academic Appointments

Professional Education

  • Board Certification: National Board of Echocardiography, Adult Echocardiography (2022)
  • Board Certification: American Board of Internal Medicine, Cardiovascular Disease (2023)
  • Board Certification, American Board of Internal Medicine, Cardiovascular Diseases (2023)
  • Board Certification, Certification Board of Cardiovascular Computed Tomography, Cardiovascular Computed Tomography (2023)
  • Cardiology Fellowship, University of California San Diego, CA (2023)
  • Board Certification, Certification Board of Nuclear Cardiology, Nuclear Cardiology (2023)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2020)
  • Residency, University of Texas Southwestern Medical Center, TX (2020)
  • Medical Education, University of Pittsburgh School of Medicine, PA (2017)
  • Bachelor of Science, University of Notre Dame, IN (2013)

Contact

  • Academic
    bryanwu@stanford.edu
    Department: Medicine - Med/Cardiovascular Medicine Position: Clinical Assistant Professor
  • Clinical (Primary)  San Jose Medical Group 2585 Good Samaritan Dr Internal Medicine San Jose, CA 95124 (408) 357-1265 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5406

All Publications

  • High-intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism Wu, B., Nieman, K., Sandoval, R. 2025

    Abstract

    Pericoronary adipose tissue (PCAT) attenuation, assessed by coronary computed tomography angiography (CCTA), is a biomarker of coronary inflammation. Mean PCAT attenuation ≥ -70.5 Hounsfield Units (HU) corresponds to elevated inflammation and a higher future risk of myocardial infarction. While statins are known to possess anti-inflammatory properties, the impact of statin intensity on vascular inflammation remains underexplored in patients with type 2 diabetes mellitus (T2DM) and coronary atherosclerosis. We aim to evaluate whether high-intensity statins are associated with lower PCAT attenuation in this high-risk cohort.We retrospectively analysed 203 CCTAs performed at our institution between 1/1/2019 and 9/1/2024 in patients with T2DM who met these key criteria: evidence of coronary atherosclerosis on CCTA, treatment with ≥1 oral hypoglycaemic agent, and no history of prior coronary interventions. PCAT attenuation was measured in the proximal right coronary artery.Among the three statin intensity groups, patients receiving high-intensity statins (n = 75) had the lowest PCAT attenuation (high-intensity: -75.0 ± 6.8 HU, moderate-intensity: -71.8 ± 8.2 HU, no statin: -71.6 ± 7.4 HU; adjusted p = 0.027). In addition to high-intensity statins, treatment with glucagon-like peptide-1 receptor agonist was independently associated with a lower likelihood of having elevated PCAT attenuation (≥ -70.5 HU), with an odds ratio of 0.344 (95% CI: 0.132-0.900).In patients with T2DM and coronary atherosclerosis, high-intensity statin therapy was associated with lower coronary inflammation. Our findings emphasize the need for aggressive cardiovascular prevention in this high-risk cohort.

    View details for DOI 10.1111/dom.70032

    View details for PubMedID 40826958